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Background: The search to identify disease-susceptible genes requires access to biological material from
numerous well-characterized subjects. Archived residual dried blood spot (DBS) samples, also known as Guthrie
cards, from national newborn screening programs may provide a DNA source for entire populations. Combined
with clinical information from medical registries, DBS samples could provide a rich source for productive research.
However, the amounts of DNA which can be extracted from these precious samples are minute and may be
prohibitive for numerous genotypings. Previously, we demonstrated that DBS DNA can be whole-genome
amplified and used for reliable genetic analysis on different platforms, including genome-wide scanning arrays.
However, it remains unclear whether this approach is workable on a large sample scale. We examined the
robustness of using DBS samples for whole-genome amplification following genome-wide scanning, using arrays
from Illumina and Affymetrix.
Results: This study is based on 4,641 DBS samples from the Danish Newborn Screening Biobank, extracted for
three separate genome-wide association studies. The amount of amplified DNA was significantly (P < 0.05)
affected by the year of storage and storage conditions. Nine (0.2%) DBS samples failed whole-genome
amplification. A total of 4,586 (98.8%) samples met our criterion of success of a genetic call-rate above 97%. The
three studies used different arrays, with mean genotyping call-rates of 99.385% (Illumina Infinium Human610-
Quad), 99.722% (Illumina Infinium HD HumanOmni1-Quad), and 99.206% (Affymetrix Axiom Genome-Wide CEU).
We observed a concordance rate of 99.997% in the 38 methodological replications, and 99.999% in the 27
technical replications. Handling variables such as time of storage, storage conditions and type of filter paper
were shown too significantly (P < 0.05) affect the genotype call-rates in some of the arrays, although the effect
was minimal.
Conclusion: Our study indicates that archived DBS samples from the Danish Newborn Screening Biobank
represent a reliable resource of DNA for whole-genome amplification and subsequent genome-wide association
studies. With call-rates equivalent to high quality DNA samples, our results point to new opportunities for using the
neonatal biobanks available worldwide in the hunt for genetic components of disease.
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Identifying genetic effects in complex disorders usually
requires genome studies in large cohorts. Access to
DNA from well-characterized patients and healthy con-
trols represents a major bottleneck. This problem may
be circumvented by using archived residual blood sam-
ples from newborn screening programs, which encom-
pass the entire population under a certain age in several
countries. The blood is usually collected by heel-prick
and applied to special filter paper; a proven robust and
convenient medium for transport and storage [1]. Sto-
rage policies for residual neonatal dried blood spot
(DBS) samples vary internationally, but several countries
store residual samples in repositories for research pur-
poses [2-8]. Stored DBS samples combined with relevant
clinical information from medical registries are an ideal
resource for large studies representing an entire popula-
tion under a given age without selection bias. In addi-
tion, availability of previously collected samples allows
substantial savings in research-related costs and time.
The Danish Neonatal Screening Biobank (DNSB) con-
tains nearly two million DBS samples collected from
almost every Dane born after 1981. It has recently been
updated to meet new general guidelines for the estab-
lishment and operation of biobanks [9]. Approval from
the Scientific Ethical Committee System, the Data Pro-
tection Agency, and the DNSB Steering Committee is
needed to obtain access to samples for research.
In Denmark, all citizens have a unique personal identi-
fication number used in all public registration systems,
including the DNSB. Denmark also has a well-estab-
lished public health care system with equal treatment
offered to all citizens. These resources allow researchers
to study the entire country as a cohort, and make the
DNSB an ideal resource for studying common and com-
plex genetic diseases in Caucasians [10].
A major challenge using DBS samples for genetic stu-
dies is the small amount of blood available in a spot.
The amount of genomic DNA (gDNA) that can be
extracted from a 3.2-mm punch of a DBS sample is
approximately 60 ng [11]. In general, only one or two
3.2-mm punches per DBS sample can be reserved for a
given project, limiting screening to only a few single
nucleotide polymorphisms (SNP). This obstacle may be
overcome by whole-genome amplification (WGA) of the
DNA. Previous studies have used whole-genome ampli-
fied DNA (wgaDNA) for genotyping with some success,
but in most cases, only a limited number of polymorph-
isms could be tested [11-17].
Here we describe genome-wide association studies
(GWAS) using DBS samples from the DNSB. Storage
time, storage conditions, and type of filter paper used
for DBS collection were evaluated to determine their
effects on the amount of amplified wgaDNA material
obtained from each sample. The effects of these vari-
ables on genotype call rates in three studies, using three
different types of array, running on either Illumina or
Affymetrix genotyping platforms were also examined.
Methods
Subjects
Our 4,641 subjects were obtained from three case-con-
trol GWAS studies. The first study, GEMS (Genomic
Medicine for Schizophrenia), called “610k” in this manu-
script, included 1,808 DBS samples stored from 1981-
1996. The purpose was to identify genetic regions asso-
ciated with schizophrenia (Ethical Approval no.:
20020020; Data Protection Agency no.: 2002-41-2059).
The second study, “Omni1”, provided 1,283 DBS sam-
ples stored from 1982-2006, and was undertaken to
examine the role of genetics in Meningococcal and
Pneumococcal infections (Ethical Approval nos.
20060008 and HB-2007-085; Data Protection Agency
nos. 2005-41-6012 and 2007-41-0229). The third study,
“Axiom”, aimed to identify genetic variations associated
with asthma, and included DBS samples stored from
1982-2006 (Ethical Approval no. HB-2008-103; Data
Protection Agency no. 2008-41-2622). All studies were
approved by the DNSB Steering Committee. The cur-
rent study was conducted as an anonymous register
study.
DNA extraction, whole-genome amplification, and SNP
genotyping
T w o3 . 2 - m md i s k sw e r ep u n c h e df r o me a c hD B Ss a m -
ple, and protein was removed as previously described
[18]. Genomic DNA was hereafter extracted using the
Extract-N-Amp kit (Sigma-Aldrich). To attenuate possi-
ble unequal amplification of alleles, WGA was carried
out in triplicate using the REPLI-g mini kit (Qiagen).
The concentration of wgaDNA was estimated using
Quant-IT PicoGreen dsDNA Reagent (Invitrogen). The
three studies, “610k”, “Omni1” and “Axiom” used an
Infinium Human610-Quad chip array (Illumina), an Infi-
nium HD HumanOmni1-Quad chip array (Illumina) and
an Axiom Genome-Wide CEU Array chip (Affymetrix),
respectively. wgaDNA samples were normalized to 60
ng/μL prior to genome wide scanning (GWS) of SNP
genotypes. Samples with genotyping call rates (GCR)
below 97% but above 95% were rerun in the Illumina-
based studies without reamplifying the gDNA samples,
under the assumption that the low call-rates stemmed
from a technical issue. Samples with GCRs below 95%
were re-amplified before re-genotyping. Both technical
replicates (same wgaDNA genotyped twice) and metho-
dological replicates (same sample of WGA used in two
separate reactions and genotyped separately) were
included in the two Illumina studies. “610k” included six
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included 32 methodological and 16 technical replicates,
and “Axiom” had no replicates.
Statistical evaluation
To evaluate the sample processing we pooled the DBS
samples included in the three GWAS studies. Pooling
samples was statistically sound as all samples were trea-
ted identically up to the step before choosing the SNP
genotyping array platform and technology, but possible
sample effects were tested statistically. We used a linear
regression model to test for interaction between the
included variables: years of storage counting from 1981
(years), storage conditions (condition: 0 (+4°C, 1981-
1987), 1 (-20°C, 1988-present)), type of filter paper (fil-
ter: 0 (S&S2992, 1981-2000), 1 (S&S903, 2001-present))
and the wgaDNA concentration.
The GCR was used for evaluating the array efficiency
and sensitivity to biobank variables. To meet the criteria
of being normally distributed, the GCR was transformed
using a zero-skewness log (resulting in log(1-GCR), the
logarithm of the failure rate). The effect of the years of
storage, type of filter paper, and storage conditions on
the transformed GCR was analysed in the three studies
individually using a linear regression interaction model.
A bivariate linear regression model was used to evaluate
the effect of the wgaDNA concentration on the GCR.
STATA MP11 software (StataCorp LP, TX, USA) was
used for the statistical analyses.
Results
Subjects
A total of 4,641 subjects from the three GWAS disease
s t u d i e sw e r eu s e dt oe v a l u a t et h eu s eo fD B Ss a m p l e s
for genetic studies. “610k” included 1,808 samples stored
for a mean of 23.9 years (range: 14-28 years; standard
deviation (SD): 2.8 years; 45.5% female and 54.5% male).
“Omni1” was based on 1,283 samples stored for a mean
of 15.7 years (range: 4-28 years; SD: 6.2 years; 43.6%
female and 56.4% male). “Axiom” included 1,550 sam-
ples stored for a mean of 16.5 years (range: 4-28 years;
SD: 6.5 years; 31.8% female and 68.2% male).
Biobank evaluation
As the three studies used the same sample preparation
process, we were able to pool their results to evaluate
the method. As both storage conditions and filter paper
are time dependent, bivariate analysis was not appropri-
ate. Results of the multiple regression models sum-
marised in Table 1. A graphical representation of the
model is shown in Figure 1 (wgaDNA concentration
graph). The mean wgaDNA concentration (Total
volume: 180 μL) of the 4,597 DBS samples was 135 ng/
μL, ranging from 5-442 ng/μL, and with a standard
d e v i a t i o no f5 1n g / μL. The type of filter paper did not
significantly affect the wgaDNA concentration, nor did
it significantly change the effect of time of storage.
However, the wgaDNA concentration was significantly
lower in the older samples, with each year of storage
accounting for an average loss of 10.4 ng/μL per year.
The negative effect of time of storage was significantly
decreased if the samples were stored at -20°C shortly
after reception; the rate of degradation reduced to 2.67
ng/μL per year.
Technical evaluation
In the “610k” and “Omni1” studies, 60 and 18 samples,
respectively, failed to meet our predefined GCR criterion
of > 97% and were requeued (Table 2). Eleven samples
in the “610k” study and five in the “Omni1” study failed
to reach the CGR criterion in the second run. A total of
98.8% of samples in the “610k” study and 99.6% in the
“Omni1” s t u d yw e r es u c c e s s f u l l yg e n o t y p e d( T a b l e2 ) .
Table 1 Effect of storage year, storage conditions, and
type of filter paper on the wgaDNA concentration
Coef. 95%CI Std.Err. p-value
Year 10.4 (9.39; 11.5) 0.531 0.000
Condition 37.6 (30.5; 44.7) 3.62 0.000
Condition*Year -7.74 (-8.87; -6.61) 0.577 0.000
Filter Paper 2.68 (-81.9; 87.3) 43.2 0.950
Filter Paper*Year 0.193 (-3.63; 4.01) 1.95 0.921
Constant 77.4 (73.6; 81.2) 1.93 0.000
Multiple linear regression model testing for interaction between the included
variables: storage year (Year), storage conditions (Condition: +4°C vs. -20°C),
type of filter paper (Filter Paper: S&S2992 vs. S&S903) and the wgaDNA
concentration. Coef.: regression coefficient. 95%CI: 95% Confidence interval.
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Figure 1 Regression model predicted wgaDNA concentrations
and GCR by storage year. The predicted effect of the year of
initial storage on the GCR in the three case-control studies (blue:
610k; green: Axiom; red: Omni19) are shown on the primary (left) y-
axis. The secondary (right) y-axis shows the predicted wgaDNA
concentration (purple line) over the year of initial storage.
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twice and genotyped separately) were repeated six times
in “610k” and 32 times in “Omni1”, with concordance
rates of 99.999 and 99.994%, respectively. Technical
samples (the same wgaDNA sample run twice on sepa-
rate chips) were replicated 11 times in “610k” and 16
times in “Omni1”, with concordance rates of 99.950 and
99.998%, respectively.
Array evaluation
The three GWAS studies were evaluated separately as
their performance was significantly different (data not
shown), likely because different array types were used
on different genotyping platforms (Affymetrix and
Illumina).
T h em e a nG C R si nt h et h r e es t u d i e sw e r e :“610k”,
99.385385% (range: 47.129-99.933%; GCR 5th percentile:
98.609%); “Omni1”, 99.722 (range: 55.685-99.974%; GCR
5th percentile: 99.522%); and “Axiom”, 99.206% (range:
89.313-99.890%; GCR 5th percentile: 98.140%).
Considering that wgaDNA concentration is an inter-
mediate variable between GCR and years of storage and
storage conditions (Table 1), we did not include it in
the model for GCR, but analysed it as a single factor
using linear regression. An increasing wgaDNA concen-
tration was found to positively affect the GCR in the
Omni1 (P < 0.001), and Axiom (P = 0.013) arrays,
whereas the 610k array (P = 0.228) was not significantly
affected. The multiple-linear regression models with
interactions showed: storage conditions, years of storage
and filter paper type were significantly associated to the
GCR in at least one of the three arrays (Table 3). For
the Omni1 array we saw a significant association
between the type of filter paper and the GCR, suggesting
that samples collected on S&S2992 filter paper perform
better than samples collected on S&S903 filter paper.
Furthermore, the “filter*years” interaction variable indi-
cated that the GCR decreases more rapidly over time on
S&S903 paper (as is also indicated by the steeper curve
in Figure 1). Samples genotyped with the Axiom array,
stored at -20°C had significantly higher GCRs than sam-
ples stored at +4°C, but the effect of storage years on
GCR was reversed when storing at -20°C. “610k” did not
include samples collected on S&S903 filter paper, and
neither storage time nor conditions affected the GCR.
Discussion
Dried blood spot samples are being collected and stored
in biobanks for diagnostic and research purposes world-
wide. In several countries this has been common prac-
tice for several decades. We previously showed that DBS
samples from the DNSB can be used to generate reliable
genetic results using the Illumina genome-wide scanning
technology, but this evaluation was restricted to rela-
tively few samples [19]. In the current study, which
combined results from three recent GWS studies, we
f o u n dt h a tD B Ss a m p l e sa r esuitable for large-scale
genetic studies [20].
S t o r a g et i m ei n f l u e n c e dt h ew g a D N Aa m p l i f i c a t i o n
negatively, with significantly lower concentrations in the
older samples (Table 1)(Figure 1)(Figure 2). The concen-
tration was lowest in samples from 1981-82, and slowly
increased for samples until 1988-90. Concentrations
then remained relatively stable until 2001-02, and then
Table 2 Technical evaluation of the “610k”, “Omni1”, and
“Axiom” studies
“610k”“ Omni1”“ Axiom”
Subjects 1808 (100) 1283 (100) 1550 (100)
Positive amplification 1799 (99.5) 1283 (100) 1550 (100)
Successful genotyping 1778 (98.8) 1278 (99.6) 1530 (98.7)
Requeue 60 (3.34) 18 (1.40)
Successfully requeued 39 (65.0) 13 (72.2)
Methodological replicates 6 (99.999) 32 (99.994)
Technical replicates 11 (99.950) 16 (99.998)
Number and percentage (%) of included subjects. Subjects: number of
subjects initially included. Positive amplification: number of subjects with a
successful WGA reaction (conc. > 30 ng/ul). Requeue: gDNA samples failing to
reach initial successful genotyping criteria that were whole-genome amplified
and genotyped a second time. Successfully requeued: The number of
requeued samples successfully genotyped. Methodological replicates: the
same gDNA sample amplified twice and genotyped separately. Technical
replicates: the same wgaDNA sample run twice on separate chips.
Table 3 The effect of biobank-related variables on log(1-GCR) in three GWS arrays
“610k”“ Omni1”“ Axiom”
Coef. 95%CI p-value Coef. 95%CI p-value Coef. 95%CI p-value
Year -0.016 (-0.040; 0.009) 0.204 -0.004 (-0.080; 0.072) 0.921 -0.195 (-0.238; -0.151) 0.000
Condition 25.1 (-107; 157) 0.710 -30.3 (-185; 124) 0.701 -484 (-574; -394) 0.000
Condition*Year -0.013 (-0.079; 0.054) 0.712 0.015 (-0.063; 0.093) 0.703 0.243 (0.198; 0.289) 0.000
Filter paper 357 (108; 606) 0.005 -40.1 (-222; 142) 0.666
Filter paper*Year -0.178 (-0.303; -0.054) 0.005 0.020 (-0.071; 0.111) 0.667
Constant 25.3 (-23.0; 73.6) 0.304 0.798 (-150; 152) 0.992 381 (294; 468) 0.000
Included variables: Storage year (Year), storage conditions (Condition: +4°C vs. -20°C), type of filter paper (Filter paper: S&S2992 vs. S&S903) and the interaction
variables Condition*Year, and Filter Paper*Year, and the GCR. Coef.: regression coefficient. 95%CI: 95% Confidence interval. A p-value of 0.000 is to be interpreted
as being below 0.0001.
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was to store the samples at +4°C for up to a year before
t r a n s f e r r i n gt h es a m p l et o- 2 0 ° C ,p o s s i b l yi n c r e a s i n g
fragmentation of the spot DNA, and lowering the qual-
ity of the DNA.
According to our regression model, and as suggested in
a previous study [17], increasing years of storage and sto-
rage at+4°C negatively affected the wgaDNA concentra-
tion (Table 1). Independent of years of storage, the
wgaDNA concentration increased when DBS samples
were stored at -20°C shortly after reception, thereby
increasing the chance of a successful WGS (Table 1). In
contrast to a previous finding [17], the more absorbent
S&S903 filter paper did not significantly affect the
amount of amplified material compared to the less absor-
bent S&S2992 filter paper (Table 1) [17]. As only 8.6%
(396) of the samples were spotted on S&S903 filter paper,
we would like to expand this analysis when new studies
have provided additional data from S&S903 samples.
The wgaDNA samples in the three studies performed
excellently, with mean GCRs greater than 99.2%, and
replication concordance rates greater than 99.9% (Table
2). This indicates that gDNA extracted from DBS sam-
ples, amplified under suboptimal conditions (gDNA
input below 10 ng), can be used as a reliable DNA
resource for high-throughput SNP genotyping. With this
in mind, we aimed to detect if any biobank-related vari-
ables affected the GCR.
In “Omni1” and “Axiom”,b u tn o t“610k”, increasing
wgaDNA concentrations increased the GCR. We specu-
lated as to whether the lack of association in “610k” was
due to the fact that the study only included samples
from 1981-1996, whereas the other studies incorporated
samples stored from 1982-2006.
In contrast to what we expected, the less absorbent
S&S2992 filter paper had significantly higher GCRs in
“Omni1”, compared with the absorbent S&S903. The
statistical model also indicated that the GCRs in the
S&S903 samples of the"Omni1” increased significantly
with fewer years of storage, suggesting that the GCRs
over time decrease at a higher rate. Overall, relatively
few samples were collected on the S&S903 filter paper
(196 (~15%) in “Omni1” and 200 (~13%) in “Axiom”),
so the significant associations could also be artefacts.
Future studies will help us to answer this question.
The storage conditions significantly affected the GCR
in the “Axiom” study, with the GCR increasing when
samples were stored at -20°C. Unexpectedly, the older
samples performed better than the more recent samples.
We speculate that the difference between the Affymetrix
(ligation) and Illumina (single base extension) SNP gen-
otyping approaches may contribute to this. Overall, of
the three arrays tested, the Illumina “Omni1” array per-
formed best. Compared with the other arrays, “Omni1”
had the highest mean GCR, and the highest sample suc-
c e s sr a t e .I ti si m p o r t a n tt op o i n to u tt h a tn o n eo ft h e
arrays performed poorly, and that the effects of the dif-
ferent variables on the GCR were minimal, even when
statistically significant. All three arrays should be con-
sidered usable for GWS of DBS samples.
The robustness of the three GWS studies indicates
that filter paper is an excellent way to collect and store
whole blood samples for later DNA research purposes.
Collecting samples on filter paper has several advantages
compared with standard venepuncture, including less
discomfort for the patient, especially if several samples
need to be collected within a short period of time. The
relatively small amount of blood taken limits the num-
ber of analyses that can be performed, but techniques
such as WGA help mitigate these restrictions with
regard to DNA based methods. To date, DBS samples
have been used for multiplex protein analysis [21], Vita-
min D estimation [22], mRNA profiling [23], cytomega-
lovirus identification [24], and epigenetic methylation
testing [25]. These studies, combined with the ability to
perform a full genetic SNP profile that we describe here,
show that consider DBS biobanks can be considered
sources for sample material for future studies of disease.
It remains to be seen whether DBS samples can be used
for next-generation sequencing, universal epigenetic
profiling or detection of copy number variations.
Conclusion
In summary, we found that DNSB DBS samples consti-
tute a good resource for SNP genotyping and GWS
array studies. Samples in neonatal screening biobanks
worldwide should be considered an important source of
genetic material for future genetic studies. Our results
Figure 2 Effect of years of storage on wgaDNA concentration.
The X-axis represents the year of initial storage of DBS sample, and
the y-axis shows the wgaDNA concentration in ng/uL. Black dots
represent outlier values, and the adjacent lines the upper and lower
adjacent values. The upper and lower hinges represent the75
th and
25
th percentile values, respectively, and median values are marked
inside the box.
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can be collected on filter paper with minimal discomfort
for patients, potentially higher participation rates, and
convenience in collection, shipping, costs, and storage as
compared with whole blood obtained by venepuncture.
Depending on the array chosen, different variables may
marginally affect the GCR, but overall our approach
using DBS samples stored for up to 28 years performed
as well as good quality DNA from whole-blood samples.
Though not significantly affecting the GCR, we empha-
size the importance of storing DBS samples at-20°C, to
enhance the numbers of biomarkers that can be
analysed.
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